🎉 Innovation Spotlight at Pharmidex! 🎉
May 27, 2025
We are proud to announce the integration of the
Jess™ /
Wes™
Automated Western Blotting Systems by Bio-Techne into our platform bringing next-generation protein analysis capabilities to our drug discovery and development workflows.
These Simple Western™ systems transform traditional Western blotting by automating and streamlining the entire process, delivering:
✅ High sensitivity and quantitation down to picogram levels
✅ Hands-free automation with results in just 3 hours
✅ Reproducible, publication-quality data
✅ Minimal sample and reagent use
✅ Multiplex detection with chemiluminescence or fluorescence
This technology allows
Pharmidex to generate fast, reproducible and quantitative protein data, enabling our clients and collaborators to accelerate biomarker validation, mechanism-of-action studies, and more.
Another step forward in our mission to support smarter, faster drug development.
We’re excited to announce that Pharmidex will be exhibiting at the BMCS 5th Synthesis in Drug Discovery and Development Conference, taking place from Tuesday 3rd to Wednesday 4th June 2025 🔗 https://lnkd.in/e_GJM8S7 Our Business Development Manager, J anette Dalay Robertson , will be attending and is looking forward to engaging with fellow professionals to foster collaborations and explore how Pharmidex can support your drug discovery and development journey. Whether you're looking for expertise in in silico, ADME, DMPK, bioanalysis, or neuroscience models, stop by our booth and let’s connect! 💬 Don’t miss the chance to meet Janette Dalay Robertson and discover how Pharmidex promotes scientific excellence through flexible, high-quality preclinical research partnerships.
At Pharmidex , we stand in solidarity with all patients, families, and healthcare professionals impacted by blood cancers. This day is a powerful reminder of the urgent need for continued innovation, collaboration, and compassion in the fight against these life-threatening diseases. Through our cutting-edge preclinical services, including: PK/ADME studies CNS penetration & efficacy models in vivo/in vitro pharmacology bioanalytical and regulatory support we contribute to the development of safer, more effective therapies for blood cancers. 🧬 We’re proud to collaborate with leading biopharma companies, academic institutions, and charities to accelerate the discovery and delivery of new treatments. ❤️ Today, we renew our commitment to this mission working towards a future where every patient has access to a cure. 🔗 Learn more and support the cause: https://www.dkms.org.uk
At Pharmidex , we help drug developers move faster and smarter with high-quality PK/PD assessments and bioanalytical services across a range of therapeutic areas. 🔬 Our team combines: Bespoke In vivo PK/PD & CNS penetration studies Wild-type, immunodeficient & humanised rodent models Advanced platforms: LC-MS/MS, qPCR, ELISA 🧠 Whether you're working on CNS drugs, oncology assets, or rare disease therapies, we deliver high quality data to drive confident decisions from lead optimisation to IND-enabling studies. ✨ Need to evaluate: BBB penetration? Target tissue exposure? PK profiling of small molecules or biologics? We’ve got you covered. 📨 Let’s talk see how Pharmidex can support your next breakthrough: 🌐 www.pharmidex.com
